At Gilead, we’re creating a healthier world for all people. For more than 35 years, we’ve tackled diseases such as HIV, viral hepatitis, COVID-19 and cancer – working relentlessly to develop therapies that help improve lives and to ensure access to these therapies across the globe. We continue to fight against the world’s biggest health challenges, and our mission requires collaboration, determination and a relentless drive to make a difference.

Every member of Gilead’s team plays a critical role in the discovery and development of life-changing scientific innovations. Our employees are our greatest asset as we work to achieve our bold ambitions, and we’re looking for the next wave of passionate and ambitious people ready to make a direct impact.

We believe every employee deserves a great leader. People Leaders are the cornerstone to the employee experience at Gilead and Kite. As a people leader now or in the future, you are the key driver in evolving our culture and creating an environment where every employee feels included, developed and empowered to fulfil their aspirations. Join Gilead and help create possible, together.

Job Description

Key Responsibilities:

Nonclinical Safety and Pathobiology (NSP) group is responsible for design, implementation, oversight and analysis of nonclinical programs to support drug development candidates from research to registration.
NSP group is comprised of Toxicology, Pathology, and Environmental / Occupational Toxicology.
NSP is responsible for ensuring patient safety of Gilead drug candidates through exhaustive non-clinical evaluations.
NSP is responsible for ensuring global compliance with worldwide regulations governing the conduct of Gilead’s nonclinical studies in support of global clinical trials, registration, and new drug approvals.
NSP is responsible for Pathobiology characterization of animal models and clinical specimens as needed to advance translational understanding of new targets and new therapeutics.
Manages and mentors a group of Ph.D. level toxicologists and pathologists to ensure NSP continues to develop and implement cutting edge scientific technologies and drug development strategies.
Prepares and reviews regulatory documents including INDs/IMPDs, Investigator Brochures and NDAs/MAAs.
Communicates successfully cross-functionally to accomplish Company goals.
Solves highly complex problems requiring evaluation of business intangibles in addition to thorough scientific assessment.

Knowledge:

Experience in successful conduct of nonclinical programs as well as preparation, submission and approval of nonclinical sections of regulatory filings covering all stages of development.
Has an in-depth knowledge of nonclinical drug discovery and development and regulatory environments in the US, EU and AsiaPac.
Individual is recognized as an expert in the field both inside and outside of the company.
Possesses strong leadership/management abilities and is highly effective on teams.
Possesses strong organizational skills, technical excellence, scientific creativity and critical thinking ability.
Maintains broad knowledge of scientific discipline. Expected to provide oversight of the following areas:
Discovery support screening studies for candidate selection
Development support GLP toxicity studies (to enable IND/IMPD and NDA/MAA submissions)
Preparation of nonclinical regulatory documentation
Issue resolution
Qualification of impurities
Environmental assessments

Specific Education and Experience Requirements

Requires a Ph.D in pharmacology/toxicology/pathology or related scientific discipline, together with a significant amount of experience that has led to a reputation as a leader in the field.

DABT and/or DACVP and/or ERT preferred.
Knowledge of global regulatory guidelines associated with quality and compliance in the conduct of nonclinical safety studies is required.
Should have at least 20 years of experience in research or development in a pharmaceutical company or contract research organization.
Ability to collaborate across a global network of stakeholders to ensure delivery of drug candidates.

People Leader Accountabilities

Create Inclusion - knowing the business value of diverse teams, modelling inclusion and embedding the value of diversity in the way they manage their teams.
Develop Talent - understand the skills, experience, aspirations and potential of their employees and coach them on current performance and future potential. They ensure employees are receiving the feedback and insight needed to grow, develop and realize their purpose.
Empower Teams - connect the team to the organization by aligning goals, purpose, organizational objectives and holding them to account. They provide the support needed to remove barriers and connect their team to the broader ecosystem.

For jobs in the United States:

Gilead Sciences Inc. is committed to providing equal employment opportunities to all employees and applicants for employment, and is dedicated to fostering an inclusive work environment comprised of diverse perspectives, backgrounds, and experiences. Employment decisions regarding recruitment and selection will be made without discrimination based on race, color, religion, national origin, sex, age, sexual orientation, physical or mental disability, genetic information or characteristic, gender identity and expression, veteran status, or other non-job related characteristics or other prohibited grounds specified in applicable federal, state and local laws. In order to ensure reasonable accommodation for individuals protected by Section 503 of the Rehabilitation Act of 1973, the Vietnam Era Veterans' Readjustment Act of 1974, and Title I of the Americans with Disabilities Act of 1990, applicants who require accommodation in the job application process may contact [email protected] for assistance.

For more information about equal employment opportunity protections, please view the 'Know Your Rights' poster.

NOTICE: EMPLOYEE POLYGRAPH PROTECTION ACT
YOUR RIGHTS UNDER THE FAMILY AND MEDICAL LEAVE ACT

Gilead Sciences will not discharge or in any other manner discriminate against employees or applicants because they have inquired about, discussed, or disclosed their own pay or the pay of another employee or applicant. However, employees who have access to the compensation information of other employees or applicants as a part of their essential job functions cannot disclose the pay of other employees or applicants to individuals who do not otherwise have access to compensation information, unless the disclosure is (a) in response to a formal complaint or charge, (b) in furtherance of an investigation, proceeding, hearing, or action, including an investigation conducted by the employer, (c) consistent with the legal duty to furnish information; or (d) otherwise protected by law.

Our environment respects individual differences and recognizes each employee as an integral member of our company. Our workforce reflects these values and celebrates the individuals who make up our growing team.

Gilead provides a work environment free of harassment and prohibited conduct. We promote and support individual differences and diversity of thoughts and opinion.

For Current Gilead Employees and Contractors:

Please apply via the Internal Career Opportunities portal in Workday.

About the company

Gilead Sciences is a biopharmaceutical company that discovers, develops and sells medicines for HIV, viral hepatitis and other liver diseases, cancer and inflammatory conditions. Its HIV business covers both treatment, led by the once-daily pill Biktarvy, and prevention, including Descovy and Yeztugo, a lenacapavir injection given twice a year. In cancer, its Kite unit makes CAR T-cell therapies from patients' own immune cells, and Trodelvy is an antibody-drug conjugate for breast cancer. Gilead earns revenue by selling its drugs to wholesalers, specialty pharmacies, hospitals and governments worldwide after regulatory approval. The company was founded in 1987 and is headquartered in Foster City, California.

Company Size

10,001+

Company Stage

IPO

Headquarters

Foster City, California

Founded

1987

Get referred to Gilead Sciences

See people who can refer or advise you

Simplify's Take

What believers are saying

Gilead is expanding at headquarters: it broke ground on a Foster City biologics plant in August 2026.
Its top seller has a long runway: generic deals keep US copies of Biktarvy off shelves until April 2036.
Acquisitions add teams to join: Gilead bought German drug developer Tubulis for about $3.2 billion in May 2026.

What critics are saying

Sales lean on one disease: HIV drugs made $5.7 billion of Gilead's $7.8 billion revenue in Q2 2026.
Medicare will set Biktarvy's price: officials picked it in January 2026 for negotiated prices starting in 2028.
Expect cuts: Gilead reported 108 Redwood City and 51 San Mateo layoffs taking effect by June 2026.

What makes Gilead Sciences unique

Gilead sells a twice-a-year HIV prevention shot: Yeztugo replaces daily pills with two injections a year.
Gilead now fully owns a myeloma cell therapy: it bought partner Arcellx for about $7.8 billion in April 2026.
Gilead makes cell therapies in-house: Kite runs its own CAR T plants in California, Maryland and Amsterdam.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Paid family time off and paid parental time off
Generous 401(k) contribution matching
Comprehensive medical plans that cover both physical and mental healthcare
Global Wellbeing Reimbursement
Time Off
Global Volunteer Day
Giving Together Program
Employee Support Programs
Flexible Work Options

Growth & Insights and Company News

Headcount

6 month growth

1 year growth

2 year growth

Financial News

Oct 19th, 2026

Gilead's UC pill hits trial goal, stock still slips.

Gilead's UC pill hits trial goal, stock still slips. Gilead Sciences (NASDAQ: GILD) said on 19 October 2026 that its experimental ulcerative colitis pill met the main goal of a mid-stage trial. The Gilead ulcerative colitis trial, known as SWIFT, tested emvistegrast, an oral once-daily treatment, in adults with moderately to severely active disease. At the 200mg dose, 66% of patients achieved a clinical response at Week 12 under the modified Mayo score, against 37% on placebo, according to PharmaShots. Clinical remission was reached by 31% of patients on the drug, compared with 8% on placebo, Reuters reported. Trial data presented at European gastroenterology meeting. Gilead unveiled the late-breaking Phase 2 findings at United European Gastroenterology Week 2026. The company said its experimental once-daily pill reduced symptoms of the chronic bowel illness in more patients than placebo, meeting the trial's main goal, as Reuters reported. Emvistegrast, also known as GS-1427, is a selective oral alpha4beta7 integrin inhibitor. Gilead is positioning the pill against injectable biologics such as vedolizumab and oral rivals including Abivax's obefazimod in a crowded inflammatory bowel disease field. The drug showed a generally well-tolerated safety profile during the induction phase, Benzinga reported. Shares fall despite the positive readout. GILD shares closed at $153.555 on 19 October, down 1.42% on the day. Trading volume ran at 0.82 times the 20-day average, suggesting limited conviction behind the move. RBC Capital Markets had told clients the emvistegrast readout was unlikely to move the stock, according to MarketScreener. The muted reaction underlines that Street positioning, rather than the trial's raw numbers, set the terms of the share response. FINRA short-volume data for GILD in the fortnight before the announcement showed the daily short ratio moving between roughly 0.37 and 0.57, with no sustained build-up that would point to advance positioning against the news. Earnings swing colours the backdrop. The trial news lands against a volatile run of quarterly results. Gilead posted a net loss of $10,496m, or diluted earnings per share of -$8.45, for the second quarter of 2026, a sharp reversal from net income of $2,021m and EPS of $1.61 in the first quarter, according to the company's 10-Q filing with the SEC. Revenue for the second quarter came in at $7,803m, up from $6,960m in the first three months of the year, filings show. The swing follows a pattern of uneven quarters stretching back through 2024 and 2025. Gilead reported a net loss of $4,170m in the first quarter of 2024 before returning to profit of $1,614m in the second quarter that year, and has posted net income in every quarter since bar the latest one, according to EDGAR records. Quarterly revenue has climbed steadily over the period, from $6,686m in the first quarter of 2024 to $7,803m two years later. Two Gilead insiders, Andrew D. Dickinson and Johanna Mercier, filed Form 4 disclosures with the SEC on 16 October 2026, three days before the trial announcement, according to EDGAR records. The filings do not themselves indicate the direction or scale of any transactions tied to the disclosures. Macro backdrop stays mixed for pharma stocks. The readout also arrives as broader market conditions stay unsettled for healthcare names reliant on long-dated pipeline bets. The 10-year US Treasury yield stood at 5.1% as of 15 October 2026, down slightly from 5.19% a month earlier, according to Federal Reserve data. The 2-year yield sat at 4.77%, leaving the 10-year/2-year spread at 0.35 percentage points, little changed from 0.33 points previously. US consumer prices rose to an index level of 336.298 in September, up from 334.131 the prior month, Federal Reserve data show, while the unemployment rate ticked up to 4.2% from 4.1%. None of that macro data bears directly on Gilead's trial outcome, but it frames a backdrop in which investors have shown little appetite to reward clinical headlines that fall short of outright surprise. Gilead has not disclosed a timeline for advancing emvistegrast into late-stage testing. Investors will watch for further detail at the company's next quarterly results and for any read-across from rival oral IBD programmes now in development. This article is for information only and is not investment advice or a recommendation to buy or sell any asset. Markets move quickly; figures are correct as sourced at the time of writing. Always do your own research before making financial decisions.

Investing.com

Oct 19th, 2026

Gilead to present HIV and antiviral research at IDWeek 2026.

Gilead to present HIV and antiviral research at IDWeek 2026. Published Oct 19, 2026, 08:12 AM (C) Reuters FOSTER CITY, Calif. - Gilead Sciences, Inc. (NASDAQ:GILD) announced it will present 28 research findings at IDWeek 2026, scheduled for October 21-24 in Washington, D.C., according to a press release statement. The presentations will include data on Bixlenvo (bictegravir 75 mg/lenacapavir 50 mg), the company's once-daily single tablet regimen for HIV treatment in virologically suppressed adults. New analyses from the Phase 3 ARTISTRY-1 and ARTISTRY-2 studies will examine treatment outcomes in participants with comorbidities including dyslipidemia, hypertension, diabetes mellitus and renal impairment. The company will present real-world data on early U.S. adoption of Yeztugo (lenacapavir) for HIV pre-exposure prophylaxis during the first nine months following FDA approval. The oral presentation will cover adoption patterns from June 2025 through March 2026. Yeztugo is administered twice-yearly. Additional research will include final Phase 1b results for investigational GS-1179, an oral herpes simplex virus helicase-primase inhibitor being developed for suppression of recurrent genital herpes. The presentations will cover virologic efficacy, safety and tolerability data. Other studies will examine factors influencing HIV prevention access, antiretroviral therapy restart strategies, and treatment patterns in real-world settings. Data from the Phase 4 ACCELERATE Implementation Study will examine rapid antiretroviral therapy restart for people with HIV returning to care using Biktarvy. Bixlenvo is approved in the U.S. for HIV treatment but not approved outside the U.S. Yeztugo is approved in the U.S., EU, Canada, Brazil, South Africa, Australia, Zambia and Zimbabwe for HIV prevention. GS-1179 remains investigational. Included in its AI-picked strategies -1.38 (-0.88%) Real-time Data · 13:43:21 · USD Start trading GILD now Should you invest $2,000 in GILD right now? ProPicks AI evaluates GILD alongside thousands of other companies every month using 100+ financial metrics. Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias - it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if GILD is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?

Transcript Daily

Oct 18th, 2026

Gilead Sciences, Inc. $GILD stake cut by TD Waterhouse Canada Inc.

Gilead Sciences, Inc. $GILD stake cut by TD Waterhouse Canada Inc. TD Waterhouse Canada Inc. decreased its holdings in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 68.1% during the third quarter, according to its most recent filing with the SEC. The firm owned 153,802 shares of the biopharmaceutical company's stock after selling 328,399 shares during the period. TD Waterhouse Canada Inc.'s holdings in Gilead Sciences were worth $22,698,000 at the end of the most recent reporting period. A number of other institutional investors have also added to or reduced their stakes in the business. BlackRock Inc. bought a new stake in Gilead Sciences during the 2nd quarter valued at $15,393,785,000. Legal & General Group Plc bought a new position in shares of Gilead Sciences in the 2nd quarter worth $1,316,606,000. Deutsche Bank AG bought a new position in shares of Gilead Sciences in the 2nd quarter worth $918,387,000. Jupiter Topco LLC purchased a new stake in shares of Gilead Sciences during the 2nd quarter worth $448,021,000. Finally, Mitsubishi UFJ Asset Management Co. Ltd. purchased a new stake in shares of Gilead Sciences during the 2nd quarter worth $398,905,000. Hedge funds and other institutional investors own 83.67% of the company's stock. Gilead Sciences news roundup. Here are the key news stories impacting Gilead Sciences this week: * Vir oncology collaboration expands Gilead's pipeline. Gilead and Vir Biotechnology agreed to develop three novel cancer therapies, including next-generation T-cell engagers. The deal could provide Vir with up to approximately $1.74 billion in additional milestone payments, giving Gilead access to potential long-term oncology growth while diversifying its pipeline. * Investors are rotating toward defensive healthcare stocks. As investors reduce exposure to technology and chip stocks, major pharmaceutical companies - including Gilead - have traded near record highs. This rotation may be supporting demand for GILD because of the sector's defensive characteristics and potential earnings support. * Recent momentum has increased investor attention. GILD gained 2.57% in the prior session and closed at $157.48, while shares remain close to their 52-week high. Market commentary notes heightened investor interest, although analysts have expressed mixed views on the company's prospects. * Two senior executives reported planned stock sales. CFO Andrew Dickinson and insider Johanna Mercier each sold 3,000 shares at an average price of $156.22. Both transactions were executed under pre-arranged Rule 10b5-1 plans, limiting their significance as a bearish signal; each executive continues to hold a substantial position. Analyst upgrades and downgrades. A number of equities research analysts recently weighed in on GILD shares. Truist Financial raised their price objective on Gilead Sciences from $150.00 to $158.00 and gave the company a "buy" rating in a research report on Wednesday, October 7th. Royal Bank Of Canada boosted their target price on shares of Gilead Sciences from $123.00 to $126.00 and gave the stock a "sector perform" rating in a report on Thursday, October 8th. Barclays reduced their target price on shares of Gilead Sciences from $155.00 to $145.00 and set an "equal weight" rating for the company in a report on Wednesday, July 29th. Wall Street Zen raised shares of Gilead Sciences from a "hold" rating to a "buy" rating in a research report on Saturday, September 19th. Finally, Leerink Partners cut shares of Gilead Sciences from an "outperform" rating to a "market perform" rating and lowered their price target for the company from $146.00 to $127.00 in a report on Tuesday, July 21st. Twenty-three analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $159.33. Gilead Sciences price performance. NASDAQ GILD opened at $156.19 on Friday. The firm's fifty day simple moving average is $147.19 and its two-hundred day simple moving average is $137.29. The firm has a market capitalization of $193.67 billion, a P/E ratio of -58.50 and a beta of 0.31. The company has a current ratio of 1.27, a quick ratio of 1.09 and a debt-to-equity ratio of 2.03. Gilead Sciences, Inc. has a 12-month low of $114.02 and a 12-month high of $160.51. Gilead Sciences (NASDAQ:GILD - Get Free Report) last issued its quarterly earnings results on Monday, August 3rd. The biopharmaceutical company reported ($6.75) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($7.25) by $0.50. Gilead Sciences had a negative return on equity of 2.11% and a negative net margin of 10.64%. The business had revenue of $7.80 billion for the quarter, compared to the consensus estimate of $7.40 billion. During the same period in the prior year, the firm posted $2.01 earnings per share. The business's quarterly revenue was up 10.6% on a year-over-year basis. Analysts forecast that Gilead Sciences, Inc. will post -0.47 EPS for the current fiscal year. Gilead Sciences announces dividend. The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 29th. Investors of record on Tuesday, September 15th were paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 2.1%. The ex-dividend date was Tuesday, September 15th. Gilead Sciences's payout ratio is -122.85%. Insider activity. In related news, Director Jeffrey Bluestone sold 5,000 shares of the company's stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $145.02, for a total transaction of $725,100.00. Following the transaction, the director directly owned 10,066 shares of the company's stock, valued at $1,459,771.32. This represents a 33.19% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Andrew Dickinson sold 3,000 shares of the stock in a transaction dated Thursday, October 15th. The shares were sold at an average price of $156.22, for a total value of $468,660.00. Following the completion of the sale, the chief financial officer owned 161,096 shares of the company's stock, valued at approximately $25,166,417.12. This trade represents a 1.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 111,000 shares of company stock worth $15,877,860 over the last quarter. Company insiders own 0.30% of the company's stock. Gilead Sciences profile. Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious and life-threatening diseases. The company is best known for its HIV treatments, including Biktarvy, Descovy, Genvoya and Truvada, as well as therapies for chronic hepatitis B and hepatitis C. Its portfolio also includes Veklury (remdesivir), an antiviral treatment for COVID-19. Gilead has expanded into oncology and cell therapy through products such as Trodelvy and the CAR T-cell therapies Yescarta and Tecartus, which are developed and marketed through its Kite subsidiary. Want to see what other hedge funds are holding GILD? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Gilead Sciences, Inc. (NASDAQ:GILD - Free Report). Receive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.

TradingView

Oct 16th, 2026

Stocktwits biotech dealmaker: Gilead, AstraZeneca and Roche chase pipeline expansion over buyouts.

Stocktwits biotech dealmaker: Gilead, AstraZeneca and Roche chase pipeline expansion over buyouts. Key points: * Gilead Sciences partnered with Vir Biotechnology on Wednesday to discover and develop three drugs aimed at solid tumors. * AstraZeneca signed an up-to-$1.5 billion AI collaboration with insitro for MASH and cardiomyopathies. * Roche licensed Rona's drug candidate, and Zealand Pharma teamed with Generate on AI-designed proteins for differentiated obesity approaches. Large pharmaceutical companies including Gilead Sciences, Roche and AstraZeneca spent this week securing access to discovery technologies and experimental candidates that address clear biological gaps, instead of large-scale acquisitions of rival firms or approved products. Obesity and cancer remained the clear focal points, with several of the week's biggest partnerships aimed at differentiated weight-loss mechanisms or new solid-tumor approaches. Gilead Partners With Vir For New Cancer Drug Candidates Gilead Sciences (GILD) partnered with Vir Biotechnology (VIR) on Wednesday to discover and develop three drugs aimed at solid tumors. Vir will handle early discovery, design, and optimization using its AI-enabled protein engineering tools and PRO-XTEN masking technology. Gilead receives exclusive rights to nominate candidates and will lead subsequent development, manufacturing, and commercialization. Vir is eligible for $90 million upfront - $65 million in cash plus a $25 million equity investment at a premium - plus up to $45 million in near-term preclinical milestones and as much as $1.74 billion in later development, regulatory, and commercial payments, along with tiered royalties. The agreement marks Vir's second major partnership around its masking platform this year after a previous deal with Astellas and adds to Gilead's attempts to advance its cancer offerings besides its blockbuster drug Trodelvy. AstraZeneca Taps Insitro's AI Platform AstraZeneca (AZN) signed a worldwide exclusive research collaboration with privately held AI therapeutics company insitro focused on metabolic dysfunction-associated steatohepatitis (MASH) and cardiomyopathies. Insitro will apply its Virtual Human platform, which combines human and cellular data with AI, to identify causal disease biology and advance AstraZeneca-nominated targets through discovery to the development-candidate stage. AstraZeneca will lead clinical development, regulatory work, and commercialization. Insitro will receive $40 million upfront and is eligible for up to approximately $1.46 billion in discovery, development, and commercial milestones, plus single-digit royalties on potential sales. Roche, Zealand Pharma Add Differentiated Obesity Approaches Roche secured exclusive worldwide rights to Rona Therapeutics' investigational drug candidate which targets a protein predominantly expressed in fat tissues. The drug candidate is designed to selectively reduce visceral and ectopic fat while preserving lean mass - an attractive complement to currently popular obesity drug classes like GLP-1. Rona is eligible for up to $100 million in upfront and near-term payments, up to $1.06 billion in additional milestones, and tiered royalties. Separately, Zealand Pharma entered a collaboration with Generate Biomedicines (GENB) to design multispecific protein therapeutics for obesity and other metabolic diseases using Generate's generative AI platform. Generate will lead research through lead-candidate selection for two initial programs, with an option for a third; Zealand will handle clinical development, regulatory submissions, and commercialization. Generate receives $30 million upfront, up to $35 million in early preclinical milestones, and nearly $1.2 billion in total potential milestones, plus royalties. Pfizer, Galderma Make Platform And Commercial Moves Pfizer (PFE) partnered with privately-held Enodia Therapeutics on a research collaboration and license for compounds intended to block disease-driving proteins at the point of synthesis. The potential value exceeds $500 million, including an upfront payment, milestones, and royalties; Enodia will run discovery against multiple targets while Pfizer takes over later development and commercialization. How Did Retail Traders React? On Stocktwits, retail sentiment around SPDR S&P Biotech ETF (XBI) fell from bullish to neutral territory over the past 24 hours, while message volume stayed at normal levels. XBI has fallen 4% over the past week as part of a broader biotech pullback that began after its mid-August peak near $170, but it is up 22.5% year-to-date.

PharmaVoice

Oct 15th, 2026

Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers.

Gilead and Vir forge $1.9bn pact to develop next-gen T-cell engagers. Oct 15, 2026, 1:30 PM Translate article text Choose a language and wait for the translated text. This deal sees Gilead double down on TCEs, following its first bet on the modality through its buyout of autoimmune-focused Ouro Medicines.

Gilead Sciences

Vice President – Nonclinical Safety and Pathobiology

About the job